What question did this study set out to answer?

The research aims to evaluate the effectiveness of KIR-CAR T cells in treating resistant glioblastomas compared to traditional CD3-based CAR T cells.

Abstract LB138: Natural killer cell-based signaling in EGFR-targeted KIR-CAR T overcomes CD3-based CAR T functional deficits to eliminate resistant glioblastomas in vivo

View Full Paper

Ask AI

Bookmark

Authors

Demonstrates enhanced anti-tumor function in glioblastomas using KIR-CAR T cells, indicating a potential breakthrough in treatment options.

The research aims to evaluate the effectiveness of KIR-CAR T cells in treating resistant glioblastomas compared to traditional CD3-based CAR T cells.
Utilized established immunocompromised murine GBM xenograft models for in vivo testing
Compared in vitro functionalities of KIR-CAR T and CD3-based CAR T cells including cytotoxicity and cytokine release
Employed multi-chain KIR/DAP12 signaling system for improved cellular activation
KIR-CAR T cells showed significantly improved anti-tumor responses compared to CD3-based CAR T
Complete tumor regression and increased survival rates were observed in treated murine models
KIR-CAR T cells maintained similar specificities and cytokine production as CD3-based CAR T in vitro

Xu et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Demonstrates enhanced anti-tumor function in glioblastomas using KIR-CAR T cells, indicating a potential breakthrough in treatment options.